The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer

Abstract

The definitive characterization of common cancer stem cell (CSCs) subpopulations in breast cancer subtypes with distinct genotypic and phenotypic features remains an ongoing challenge. In this study, we have used a non-biased genome wide screening approach to identify transcriptional networks that may be specific to the CSC subpopulations in both luminal and basal breast cancer subtypes. In depth studies of three CSC-enriched breast cancer cell lines representing various subtypes of breast cancer revealed a striking hyperactivation of the mevalonate metabolic pathway in comparison to control cells. The upregulation of metabolic networks is a key feature of tumour cells securing growth and proliferative capabilities and dysregulated mevalonate metabolism has been associated with tumour malignancy and cellular transformation in breast cancer. Furthermore, accumulating evidence suggests that Simvastatin therapy, a mevalonate pathway inhibitor, could affect breast cancer progression and reduce breast cancer recurrence. When detailing the mevalonate pathway in breast cancer using a single-cell qPCR, we identified the mevalonate precursor enzyme, HMGCS1, as a specific marker of CSC-enriched subpopulations within both luminal and basal tumour subtypes. Down-regulation of HMGCS1 also decreased the CSC fraction and function in various model systems, suggesting that HMGCS1 is essential for CSC-activities in breast cancer in general. These data was supported by strong associations between HMGCS1 expression and aggressive features, such as high tumour grade, p53 mutations as well as ER-negativity in lymph node positive breast cancer. Importantly, loss of HMGCS1 also had a much more pronounced effect on CSC-activities compared to treatment with standard doses of Simvastatin. Taken together, this study highlights HMGCS1 as a potential

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma

“…Furthermore, high free cholesterol levels in sera from stage 2b patient samples of pancreatic cancer (Figure 3B) indicate that serum cholesterol levels alter with the progression of pancreatic cancer. Previous studies reported controversial correlations between high serum cholesterol and pancreatic cancer incidence [41,42]. Moreover, recent findings indicate that the impact of cholesterol metabolism on PC would be affected by genomic perturbations prevalent in this cancer [28].…”

A Bioinformatics Approach To Reveal Common Genes And Molecular Pathways Shared By Cutaneous Melanoma and Uveal Melanoma

“…3-hydroxy 3-methylglutaryl-CoA synthase 1, (HMGCS1) is known to be potential regulatory node of the mevalonate pathway which is further involved in tumorigenesis by positively regulating the cell proliferation, migration, invasion, and metastasis of tumor cells (18) . HMGCS1 overexpression has been observed in various cancers like breast cancer, gastric cancer, renal cancer, colon cancer, and prostate cancer.…”

MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma

“…HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1) is a potential regulatory node in the mevalonate pathway, whose up-regulation is a common transcriptional event in cancer stem cell enriched subpopulations of breast cancer cell lines [ 25 ]. Wang et al also found the expression of HMGCS1 is increased significantly in stomach adenocarcinoma samples of patients and tumorspheres of gastric cancer cells [ 26 ].…”